Gabather’s target engagement study with the lead candidate GT-002, a treatment for neuropsychiatric disorders, is expected to produce its first results by the end of the year. This according to the company’s CEO, Michael-Robin Witt, who joined BioStock for an interview.
Read the interview with Michael-Robin Witt at biostock.se:
Gabather approaching initial target engagement study results – BioStock
This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se/en/